View Item 

Show simple item record

RANKL Inhibition Through Osteoprotegerin Blocks Bone Loss in Experimental Periodontitis
dc.contributor.authorJin, Qiming
dc.contributor.authorCirelli, Joni A.
dc.contributor.authorPark, Chan Ho
dc.contributor.authorSugai, James V.
dc.contributor.authorTaba, Mario
dc.contributor.authorKostenuik, Paul J.
dc.contributor.authorGiannobile, William V.
dc.date.accessioned2018-02-05T16:32:17Z
dc.date.available2018-02-05T16:32:17Z
dc.date.issued2007-07
dc.identifier.citationJin, Qiming; Cirelli, Joni A.; Park, Chan Ho; Sugai, James V.; Taba, Mario; Kostenuik, Paul J.; Giannobile, William V. (2007). "RANKL Inhibition Through Osteoprotegerin Blocks Bone Loss in Experimental Periodontitis." Journal of Periodontology 78(7): 1300-1308.
dc.identifier.issn0022-3492
dc.identifier.issn1943-3670
dc.identifier.urihttps://hdl.handle.net/2027.42/141376
dc.publisherWiley Periodicals, Inc.
dc.publisherAmerican Academy of Periodontology
dc.subject.otherreceptor activator of nuclear factor‐kappa B ligand
dc.subject.othertherapy
dc.subject.otherperiodontal disease
dc.subject.otherosteoprotegerin
dc.subject.otherBone resorption
dc.titleRANKL Inhibition Through Osteoprotegerin Blocks Bone Loss in Experimental Periodontitis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Biomedical Engineering, College of Engineering, University of Michigan.
dc.contributor.affiliationumDepartment of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI.
dc.contributor.affiliationotherMichigan Center for Oral Health Research, Ann Arbor, MI.
dc.contributor.affiliationotherMetabolic Disorders Research, Amgen, Thousand Oaks, CA.
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141376/1/jper1300.pdf
dc.identifier.doi10.1902/jop.2007.070073
dc.identifier.sourceJournal of Periodontology
dc.identifier.citedreferencePark CH, Abramson Z, Taba M Jr., et al. 3‐D micro‐CT image analysis of alveolar bone resorption and repair. J Periodontol 2007; 78: 273 – 281.
dc.identifier.citedreferenceBucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin‐deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260 – 1268.
dc.identifier.citedreferenceMizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610 – 615.
dc.identifier.citedreferenceUdagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000; 141: 3478 – 3484.
dc.identifier.citedreferenceHasegawa T, Yoshimura Y, Kikuiri T, et al. Expression of receptor activator of NF‐kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. J Periodontal Res 2002; 37: 405 – 411.
dc.identifier.citedreferenceLiu D, Xu JK, Figliomeni L, et al. Expression of RANKL and OPG mRNA in periodontal disease: Possible involvement in bone destruction. Int J Mol Med 2003; 11: 17 – 21.
dc.identifier.citedreferenceCrotti T, Smith MD, Hirsch R, et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003; 38: 380 – 387.
dc.identifier.citedreferenceMogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004; 83: 166 – 169.
dc.identifier.citedreferenceMorony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61: 4432 – 4436.
dc.identifier.citedreferenceZhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer‐induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235 – 1244.
dc.identifier.citedreferenceCapparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000; 60: 783 – 787.
dc.identifier.citedreferenceOyajobi BO, Anderson DM, Traianedes K, Williams BJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB‐IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001; 61: 2572 – 2578.
dc.identifier.citedreferenceBekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16: 348 – 360.
dc.identifier.citedreferenceBody JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887 – 892.
dc.identifier.citedreferenceCundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM. Recombinant osteoprotegerin for juvenile Paget’s disease. N Engl J Med 2005; 353: 918 – 923.
dc.identifier.citedreferenceTeng YT, Nguyen H, Gao X, et al. Functional human T‐cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000; 106: R59 – R67.
dc.identifier.citedreferenceMahamed DA, Marleau A, Alnaeeli M, et al. G(−) anaerobes‐reactive CD4+ T‐cells trigger RANKL‐mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes 2005; 54: 1477 – 1486.
dc.identifier.citedreferenceCapparelli C, Morony S, Warmington K, et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003; 18: 852 – 858.
dc.identifier.citedreferenceRomas E, Sims NA, Hards DK, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen‐induced arthritis. Am J Pathol 2002; 161: 1419 – 1427.
dc.identifier.citedreferenceHalleen JM. Tartrate‐resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 2003; 23: 1027 – 1029.
dc.identifier.citedreferenceKostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005; 5: 618 – 625.
dc.identifier.citedreferenceFleisch H. Bisphosphonates: Mechanisms of action and clinical use in osteoporosis – An update. Horm Metab Res 1997; 29: 145 – 150.
dc.identifier.citedreferenceLane N, Armitage GC, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: Results of a 12‐month, randomized, placebo‐controlled study. J Periodontol 2005; 76: 1113 – 1122.
dc.identifier.citedreferenceRocha M, Nava LE, Vazquez de la Torre C, Sanchez‐Marin FJ, Garay‐Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo‐controlled trial. J Periodontol 2001; 72: 204 – 209.
dc.identifier.citedreferenceRocha ML, Malacara JM, Sanchez‐Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women: A randomized placebo‐controlled trial. J Periodontol 2004; 75: 1579 – 1585.
dc.identifier.citedreferenceMarx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate‐induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567 – 1575.
dc.identifier.citedreferenceBamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23: 8580 – 8587.
dc.identifier.citedreferenceKomatsubara S, Mori S, Mashiba T, et al. Long‐term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003; 18: 512 – 520.
dc.identifier.citedreferenceLin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992; 20: 473 – 478.
dc.identifier.citedreferencePage RC, Kornman KS. The pathogenesis of human periodontitis: An introduction. Periodontol 2000 1997; 14: 9 – 11.
dc.identifier.citedreferenceKirkwood KL, Cirelli J, Rogers J, Giannobile WV. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007; 43: 294 – 315.
dc.identifier.citedreferenceHofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2 – 12.
dc.identifier.citedreferenceNakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane‐bound and soluble receptor activator of NF‐kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000; 275: 768 – 775.
dc.identifier.citedreferenceKong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph‐node organogenesis. Nature 1999; 397: 315 – 323.
dc.identifier.citedreferenceSimonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309 – 319.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jper1300.pdf
Size:
22.08MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.